: A new clinical study published in The New England Journal of Medicine today and simultaneously presented during the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium claims that a drug combination
of Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients
with metastatic kidney cancer.
Researchers claimed that the combination also improved progression-free survival and overall response rate.
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
The survival benefit demonstrates that an immune checkpoint inhibitor together with a targeted kinase inhibitor drug “is important in the first-line treatment of patients with advanced renal cell carcinoma,” said the authors of the study. The senior author is Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber.
The phase 3 CLEAR study results showed significant benefits from the combination comprised of lenvatinib, an oral kinase inhibitor that targets proteins involved in the formation of blood vessels supplying a tumor, and pembrolizumab, a
… View More Researchers analyze new drug combination to improve survival in advanced kidney cancer, Health News, ET HealthWorld